Pfizer, OPKO One Step Closer to Approval of Pediatric Growth Hormone Deficiency Drug

Pfizer and OPKO Health are one step closer to receiving approval for their jointly developed pediatric growth hormone deficiency (GHD) drug, somatrogon, after the U.S. Food and Drug Administration (FDA) recently accepted the companies’ regulatory submission for the therapy.